-
1
المؤلفون: Bettina Bannert, Michael John Nissen, Silja Bühler, Claire-Anne Siegrist, Ulrich A. Walker, Carolin Brümmerhoff, Kerstin Kling, Christian Herzog, Adrian Ciurea, Veronika K. Jaeger, Niels Hagenbuch, Diego Kyburz, Rüdiger Müller, Oliver Distler, Cem Gabay, Peter M. Villiger, Christoph Hatz, Paul Hasler, Juliane Franz, Sabine Adler
المساهمون: University of Zurich, Bühler, Silja
المصدر: Rheumatology, Vol. 58, No 9 (2019) pp. 1585-1596
مصطلحات موضوعية: Male, Diphtheria-Tetanus Vaccine, 2745 Rheumatology, Booster dose, 0302 clinical medicine, Immunogenicity, Vaccine, 2736 Pharmacology (medical), Pharmacology (medical), 030212 general & internal medicine, Prospective Studies, ddc:616, Aged, 80 and over, Tetanus, Immunogenicity, Vaccination, 10051 Rheumatology Clinic and Institute of Physical Medicine, Diphtheria, Middle Aged, Antibodies, Bacterial, 3. Good health, Tetanus vaccine, Female, Safety, Vasculitis, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Immunization, Secondary, Tetanus vaccination, 610 Medicine & health, Diphtheria vaccination, complex mixtures, 03 medical and health sciences, Young Adult, Rheumatology, Internal medicine, Clostridium tetani, Rheumatic Diseases, medicine, Humans, Aged, 030203 arthritis & rheumatology, business.industry, Corynebacterium diphtheriae, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), medicine.disease, Rheumatic disease, business, Immunosuppression
الوصف: Objectives We aimed to assess the safety and immunogenicity of a diphtheria/tetanus vaccine booster dose in three different patient groups with rheumatic diseases on a variety of immunosuppressive/immunomodulatory medications compared with healthy controls (HCs). Methods We conducted a multi-centre prospective cohort study in Switzerland. We enrolled patients with RA, axial SpA/PsA, vasculitis (Behçet’s disease, ANCA-associated vasculitis) and HCs. Diphtheria/tetanus vaccination was administered according to the Swiss vaccination recommendations. Blood samples were drawn before vaccination, and 1 month and 3 months afterwards. Antibody concentrations against vaccine antigens were measured by ELISA. Immunogenicity was compared between patient and medication groups. A mixed model was applied for multivariate analysis. Missing data were dealt with using multiple imputation. Results Between January 2014 and December 2015, we enrolled 284 patients with rheumatic diseases (131 RA, 114 SpA/PsA, 39 vasculitis) and 253 HCs. Of the patients, 89% were on immunosuppressive/immunomodulatory medication. Three months post-vaccination 100% of HCs vs 98% of patients were protected against tetanus and 84% vs 73% against diphtheria. HCs and SpA/PsA patients had significantly higher responses than RA and vasculitis patients. Assessing underlying diseases and medications in a multivariate model, rituximab was the only factor negatively influencing tetanus immunogenicity, whereas only MTX treatment had a negative influence on diphtheria antibody responses. No vaccine-related serious adverse events were recorded. Conclusion Diphtheria/tetanus booster vaccination was safe. Tetanus vaccination was immunogenic; the diphtheria component was less immunogenic. Vaccine responses were blunted by rituximab and MTX. Trial registration ClinicalTrials.gov, http://clinicaltrials.govTest, Identifier: NCT01947465.
وصف الملف: ZORA_170630.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae0267135d836b3d122999fe1935525bTest
https://pubmed.ncbi.nlm.nih.gov/30877773Test -
2
المؤلفون: Anja Rosdahl, Lars Rombo, Helena H. Askling, Gert Frösner, Christian Herzog, Torbjörn Norén
المصدر: Travel medicine and infectious disease. 21
مصطلحات موضوعية: Adult, medicine.medical_specialty, medicine.medical_treatment, 030231 tropical medicine, Hepatitis A vaccine, Booster dose, Hepatitis A Antibodies, Arthritis, Rheumatoid, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Seroconversion, Hepatitis A Vaccines, business.industry, Public Health, Environmental and Occupational Health, Hepatitis A, Immunosuppression, medicine.disease, Vaccination, Infectious Diseases, Rheumatoid arthritis, Methotrexate, business, medicine.drug
الوصف: Background Previous studies have indicated that a pre-travel single dose of hepatitis A vaccine is not sufficient as protection against hepatitis A in immunocompromised travelers. We evaluated if an extra dose of hepatitis A vaccine given shortly prior to traveling ensures seroconversion. Method Patients with rheumatoid arthritis (n = 69, median age = 55 years) treated with Tumor Necrosis Factor inhibitor(TNFi) and/or Methotrexate (MTX) were immunized with two doses of hepatitis A vaccine, either as double dose or four weeks apart, followed by a booster dose at six months. Furthermore, 48 healthy individuals, median age = 60 years were immunized with two doses, six months apart. Anti-hepatitis A antibodies were measured at 0, 1, 2, 6, 7 and 12 months. Results Two months after the initial vaccination, 84% of the RA patients had protective antibodies, compared to 85% of the healthy individuals. There was no significant difference between the two vaccine schedules. At twelve months, 99% of RA patients and 100% of healthy individuals had seroprotective antibodies. Conclusion An extra priming dos of hepatitis A vaccine prior to traveling offered an acceptable protection in individuals treated with TNFi and/or MTX. This constitutes an attractive pre-travel solution to this vulnerable group of patients.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f345001c614d428fb92e1965855380Test
https://pubmed.ncbi.nlm.nih.gov/30292695Test -
3
المصدر: Vaccine. 30:989-994
مصطلحات موضوعية: Molecular Sequence Data, Sequence Homology, Yellow fever vaccine, Context (language use), Biology, Genome, Virus, medicine, Cluster Analysis, Humans, Phylogeny, Attenuated vaccine, General Veterinary, General Immunology and Microbiology, Phylogenetic tree, Yellow Fever Vaccine, Yellow fever, Public Health, Environmental and Occupational Health, Genetic Variation, Sequence Analysis, DNA, medicine.disease, Virology, Vaccination, Infectious Diseases, RNA, Viral, Molecular Medicine, Yellow fever virus, Switzerland, medicine.drug
الوصف: In recent years the safety of the yellow fever live vaccine 17D came under scrutiny. The focus was on serious adverse events after vaccinations that resemble a wild type infection with yellow fever and whose reasons are still not known. Also the exact mechanism of attenuation of the vaccine remains unknown to this day. In this context, the standards of safety and surveillance in vaccine production and administration have been discussed. Therein embodied was the demand for improved documentation of the derivation of the seed virus used for yellow fever vaccine production. So far, there was just a historical genealogy available that is based on source area and passage level. However, there is a need for a documentation based on molecular information to get better insights into the mechanisms of pathology. In this work we sequenced the whole genome of different passages of the YFV-17D strain used by Crucell Switzerland AG for vaccine production. Using all other publically available 17D full genome sequences we compared the sequence variance of all vaccine strains and oppose a phylogenetic tree based on full genome sequences to the historical genealogy.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c748210c59e287fd440a5dc49583ece2Test
https://doi.org/10.1016/j.vaccine.2011.12.057Test -
4
المصدر: Clinical and Vaccine Immunology. 15:177-181
مصطلحات موضوعية: Adult, Male, Microbiology (medical), Adolescent, Clinical Biochemistry, Immunology, Yellow fever vaccine, Viral Plaque Assay, Dengue virus, Antibodies, Viral, medicine.disease_cause, Sensitivity and Specificity, Immunoglobulin G, Serology, Plaque reduction neutralization test, parasitic diseases, Humans, Immunology and Allergy, Medicine, Serologic Tests, Fluorescent Antibody Technique, Indirect, biology, business.industry, Clinical and Diagnostic Laboratory Immunology, Flavivirus, Yellow Fever Vaccine, Yellow fever, Middle Aged, Japanese encephalitis, bacterial infections and mycoses, medicine.disease, Virology, Immunoglobulin M, biology.protein, Female, business, medicine.drug
الوصف: The first commercial indirect immunofluorescence assay (IFA) using Euroimmun Biochip technology was evaluated for the serodiagnosis of immunoglobulin G (IgG) and IgM antibodies against yellow fever virus (YFV) and was compared with the plaque reduction neutralization test (PRNT), which is currently the gold standard test for YFV. An overall correlation between the tests of 98.7% was established based on the analysis of 150 sera from individuals after vaccination with the 17D yellow fever vaccine. The sensitivity and specificity, calculated using the 150 sera from vaccinees and 150 sera from healthy blood donors, were 95% and 95%, respectively, for the IgG IFA and 94% and 97% for the IgM IFA. Antibody titers found in the PRNT correlated poorly with the IgM and IgG titers detected by IFA. The analysis of preexisting heterologous flaviviral immunity revealed the presence of antibodies reactive with YFV, tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and dengue virus serotypes 1 to 4 in 20 out of the 150 vaccinees. The indirect IFA showed that nine of these individuals with previous flaviviral exposure who received 17D vaccine failed to produce detectable IgM antibodies. Despite this preexisting immunity, all vaccinees developed protective immunity as detected by PRNT and anti-YFV IgG antibodies as detected by IFA. The high specificity and sensitivity of the IFA make it a useful tool for rapid diagnosis of yellow fever during outbreaks, for epidemiological studies, and for serosurveillance after vaccination.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6214aff59bded5538ced05c882ab533fTest
https://doi.org/10.1128/cvi.00078-07Test -
5
المؤلفون: C. Python, E. van Corven, Alexander Berthold Hendrik Bakker, Deborah J. Briggs, C.J. Kissling, Gerrit Jan Weverling, F. Uytdehaag, M.F. Brink, Jaap Goudsmit, Christian Herzog, Charles E. Rupprecht, Willem Egbert Marissen, Fija M. Lagerwerf, Stefan Kostense, S. Worst, R. Grimaldi, Katharina Hartmann, P. Pandya
المساهمون: Amsterdam institute for Infection and Immunity, General Internal Medicine
المصدر: Vaccine, 26(47), 5922-5927. Elsevier BV
مصطلحات موضوعية: Adult, Male, Adolescent, Rabies, medicine.medical_treatment, Antibodies, Viral, medicine.disease_cause, Cell Line, Young Adult, Rabies vaccine, Double-Blind Method, Neutralization Tests, medicine, Animals, Humans, Post-exposure prophylaxis, Mononegavirales, Lyssavirus, Aged, General Veterinary, General Immunology and Microbiology, biology, business.industry, Rabies virus, Immunization, Passive, Public Health, Environmental and Occupational Health, Antibodies, Monoclonal, Middle Aged, Rhabdoviridae, biology.organism_classification, medicine.disease, Virology, Vaccination, Treatment Outcome, Infectious Diseases, Rabies Vaccines, Immunology, Molecular Medicine, Female, business, medicine.drug
الوصف: Immediate passive immune prophylaxis as part of rabies post-exposure prophylaxis (PEP) often cannot be provided due to limited availability of human or equine rabies immunoglobulin (HRIG and ERIG, respectively). We report first clinical data from two phase I studies evaluating a monoclonal antibody cocktail CL184 against rabies. The studies included healthy adult subjects in the USA and India and involved two parts. First, subjects received a single intramuscular dose of CL184 or placebo in a double blind, randomized, dose-escalation trial. Second, open-label CL184 (20IU/kg) was co-administered with rabies vaccine. Safety was the primary objective and rabies virus neutralizing activity (RVNA) was investigated as efficacy parameter. Pain at the CL184 injection site was reported by less than 40% of subjects; no fever or local induration, redness or swelling was observed. RVNA was detectable from day 1 to day 21 after a single dose of CL184 20 or 40IU/kg. All subjects had adequate (>0.5IU/mL) RVNA levels from day 14 onwards when combined with rabies vaccine. CL184 appears promising as an alternative to RIG in PEP.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98edecd3817d972b363de9c069d53072Test
https://doi.org/10.1016/j.vaccine.2008.08.050Test -
6
المؤلفون: Achim Kaufhold, Oliver Kürsteiner, Helene Hilfiker, Christian Herzog, Didier Favre, Johanna L’Age-Stehr, Abdallah Ennaji, Markus F. Pfister, Peter Durrer
المصدر: The American Journal of Tropical Medicine and Hygiene. 72:339-346
مصطلحات موضوعية: Adult, Male, Yellow fever vaccine, Antibodies, Viral, Neutralization Tests, Virology, Yellow Fever, Humans, Medicine, Neutralizing antibody, Sex Characteristics, biology, business.industry, Patient Selection, Immunogenicity, Yellow Fever Vaccine, Yellow fever, Antibody titer, Middle Aged, medicine.disease, Vaccination, Titer, Infectious Diseases, Immunology, biology.protein, Female, Parasitology, Safety, Antibody, business, medicine.drug
الوصف: BERNA-YF (Flavimun) is a live, attenuated yellow fever (YF) vaccine of the 17D strain produced by Berna Biotech Ltd. following a transfer of technology from the Robert Koch Institute (RKI) in Berlin, Germany. In this phase 3 bridging study, the immunogenicity and safety of BERNA-YF were compared with the original RKI YF vaccine (RKI-YF) and to a current, commercially available YF vaccine, Stamaril (AP-YF; Aventis Pasteur, Lyon, France), in 304 healthy, adult volunteers. All three vaccines elicited an effective immune response with seroprotection achieved in 100% of individuals in each vaccine group at a neutralizing antibody titer > or = 1:10. BERNA-YF was shown to be comparable to the other two vaccine products, and subgroup analysis showed no differences in immune response between three consecutive production batches. The immune response to BERNA-YF and RKI-YF was very similar, with no significant difference in antibody titer between the two groups (P = 0.4634). However, AP-YF vaccination resulted in a significantly lower antibody titer (P < 0.0001 versus BERNA-YF). Males exhibited a higher antibody response than females to both BERNA-YF and RKI-YF, but not to AP-YF. All three vaccines were well tolerated and no serious adverse events were reported.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed0f0ff5c0b30aee6080163993c123fTest
https://doi.org/10.4269/ajtmh.2005.72.339Test -
7
المؤلفون: M. Al-Howasi, E. Gerike, A.A. Poltera, B Wegmüller, Reinhard Glück, Christian Herzog, Mohamed Khalil
المصدر: Transactions of the Royal Society of Tropical Medicine and Hygiene. 93:214-219
مصطلحات موضوعية: Time Factors, Measles-Mumps-Rubella Vaccine, Measles Vaccine, Saudi Arabia, Mumps Vaccine, Antibodies, Viral, Measles, Rubella, Immunoenzyme Techniques, Rubella vaccine, Neutralization Tests, Humans, Medicine, Rubella Vaccine, Vaccines, Combined, Seroconversion, business.industry, Public Health, Environmental and Occupational Health, Infant, General Medicine, medicine.disease, Virology, Vaccination, Infectious Diseases, Immunization, Immunology, Parasitology, Measles vaccine, business, medicine.drug
الوصف: This trial confirmed the immunogenicity of a standard dose of measles vaccine Edmonston-Zagreb strain administered at the age of 6 months as evaluated serologically at 12 months of age in 94 healthy children in Saudi Arabia. The residual seropositivity rate for measles was 53·4 and 80·6% as measured by enzyme immunoassay (EIA) and plaque neutralization, respectively, and could be increased to virtually 100% seroprotection after immunization with 1 of 2 measles-mumps-rubella (MMR) vaccines (Triviraten Berna® or MMR II® MSD) at 12 months of age. In both groups, more than 90% of infants showed an immune response to the mumps and rubella vaccine strains at 14 months of age. There was a difference in the geometric mean titres of mumps antibodies in favour of MMR II (P < 0·001). The seroconversion rates for mumps antibodies differed between the 2 vaccines because of the different test systems and/or the different cut-off levels used. The study reconfirmed that for the assessment of Rubini mumps vaccineinduced antibodies the indirect immunofluorescence test is superior to the EIA. The systemic tolerability of both vaccines was excellent. Triviraten Berna is exclusively propagated on human diploid cell cultures and hence free of avian proteins.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1399e46e90e0eb0b8920e3750d3dda49Test
https://doi.org/10.1016/s0035-9203Test(99)90310-3 -
8
المؤلفون: Cheng Yang, Christian Herzog, Varsha Kaushal, Gur P. Kaushal
المصدر: Autophagy. 4:710-712
مصطلحات موضوعية: Cisplatin, Programmed cell death, Time Factors, Autophagy, Acute kidney injury, Antineoplastic Agents, Apoptosis, Epithelial Cells, Cell Biology, Biology, medicine.disease, Nephrotoxicity, Cell biology, Kidney Tubules, medicine, Animals, Humans, Kidney Diseases, Fragmentation (cell biology), Cytotoxicity, Molecular Biology, medicine.drug
الوصف: One of the major side effects of cisplatin chemotherapy is toxic acute kidney injury due to preferential accumulation of cisplatin in renal proximal tubule epithelial cells and the subsequent injury to these cells. Apoptosis is known as a major mechanism of cisplatin-induced cell death in renal tubular cells. We have also recently demonstrated that autophagy induction is an immediate response of renal tubular epithelial cell exposure to cisplatin. Inhibition of cisplatin-induced autophagy blocks the formation of autophagosomes and enhances cisplatin-induced caspase-3, -6, and -7 activation, nuclear fragmentation and apoptosis. The switch from autophagy to apoptosis by autophagic inhibitors suggests that autophagy induction was responsible for a pre-apoptotic lag phase observed on exposure of renal tubular cells to cisplatin. Our studies provide evidence that autophagy induction in response to cisplatin mounts an adaptive response that suppresses and delays apoptosis. The beneficial effect of autophagy has a potential clinical significance in minimizing or preventing cisplatin nephrotoxicity.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5fdd0f64a32d43e99a9b81272b1479Test
https://doi.org/10.4161/auto.6309Test -
9
المؤلفون: Christian Herzog, Ka Wah Chan, Norman Jaffe, L L Chan, Ayten Cangir, R. B. Raney, J. Ater, Steven J. Culbert
المصدر: Journal of Pediatric Hematology/Oncology. 18:63-67
مصطلحات موضوعية: Male, medicine.medical_specialty, Adolescent, Cyclophosphamide, medicine.medical_treatment, Cardiomyopathy, Sarcoma, Ewing, Gastroenterology, Drug Administration Schedule, Neuroblastoma, Neoplasms, Internal medicine, Granulocyte Colony-Stimulating Factor, Humans, Medicine, Child, Antineoplastic Agents, Alkylating, Mesna, Osteosarcoma, Chemotherapy, business.industry, Infant, Sarcoma, Hematology, medicine.disease, Surgery, Ciprofloxacin, Treatment Outcome, Oncology, Child, Preschool, Pediatrics, Perinatology and Child Health, Toxicity, Feasibility Studies, Female, business, Uroprotective Agent, medicine.drug, Hemorrhagic cystitis
الوصف: Purpose : The objective of this study was to determine the tolerance and toxicities of high-dose cyclophosphamide (CPA) at 7 g/m 2 given in four fractions over 8 h in children with advanced solid tumors. Patients and Methods : Twenty children aged 1 1/2-19 years (median, 12 years) received 24 courses of high-dose CPA at 7 g/m 2 for the treatment of advanced malignant solid tumor. CPA was given in four 1-h infusions of 1.75 g/m 2 each, with 1 h of rest between each dose. MESNA was used as a uroprotective agent and was continued for 24 h after the final dose of CPA. With only one exception, all patients were discharged at the end of MESNA infusion and received granulocyte colony-stimulating factor, prophylactic ciprofloxacin, and co-trimoxazole. Results : Severe but transient myelosuppression was observed. The median time to neutrophil and platelet recovery was 17 and 19 days, respectively. Fever developed after 13 of the 24 courses, and hospitalization was required. Extramedullary toxicities were mild. No patient showed cardiomyopathy or hemorrhagic cystitis. Forty-six percent of the courses were managed entirely on an outpatient basis. Objective tumor response was seen in five patients. Conclusions : CPA at 7 g/m 2 is well tolerated by children with advanced malignancies and should be considered in earlier phases of antineoplastic therapy.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78cdaf6129561bd48acd9a46370c33fTest
https://doi.org/10.1097/00043426-199602000-00012Test -
10
المؤلفون: Christian Herzog, Cheng Yang, Rohit Seth, Gur P. Kaushal, Ling Liu
المصدر: Biochemical pharmacology. 79(2)
مصطلحات موضوعية: Male, Programmed cell death, Swine, Blotting, Western, Antineoplastic Agents, Mitochondrion, Pharmacology, Biology, Kidney, Biochemistry, Nephrotoxicity, chemistry.chemical_compound, Mice, MG132, medicine, Animals, Immunoprecipitation, Protease Inhibitors, cardiovascular diseases, Cisplatin, Mitochondria, Mice, Inbred C57BL, chemistry, Apoptosis, Proteasome inhibitor, Apoptosis-inducing factor, LLC-PK1 Cells, biological phenomena, cell phenomena, and immunity, Proteasome Inhibitors, medicine.drug
الوصف: We demonstrate the effect of proteasome inhibitors in mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-exposed renal tubular epithelial cells (LLC-PK(1) cells) and in a model of cisplatin nephrotoxicity. Immunofluorescence and subcellular fractionation studies revealed cisplatin-induced translocation of AIF from the mitochondria to nucleus. Mcl-1, a pro-survival member of the Bcl-2 family, is rapidly eliminated on exposure of renal cells to cisplatin. Proteasome inhibitors PS-341 and MG-132 blocked cisplatin-induced Mcl-1 depletion and markedly prevented mitochondrial release of AIF. PS-341 and MG132 also blocked cisplatin-induced activation of executioner caspases and apoptosis. These studies suggest that proteasome inhibitors prevent cisplatin-induced caspase-dependent and -independent pathways. Overexpression of Mcl-1 was effective in blocking cisplatin-induced cytochrome c and AIF release from the mitochondria. Downregulation of Mcl-1 by small interfering RNA promoted Bax activation and cytochrome c and AIF release, suggesting that cisplatin-induced Mcl-1 depletion and associated Bax activation are involved in the release of AIF. Expression of AIF protein in the mouse was highest in the kidney compared to the heart, brain, intestine, liver, lung, muscle, and spleen. In an in vivo model of cisplatin nephrotoxicity, proteasome inhibitor MG-132 prevented mitochondrial release of AIF and markedly attenuated acute kidney injury as assessed by renal function and histology. These studies provide evidence for the first time that the proteasome inhibitors prevent cisplatin-induced mitochondrial release of AIF, provide cellular protection, and markedly ameliorate cisplatin-induced acute kidney injury. Thus, AIF is an important therapeutic target in cisplatin nephrotoxicity and cisplatin-induced depletion of Mcl-1 is an important pathway involved in AIF release.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e986c4ea89751a2b2f010b93fd126b1Test
https://pubmed.ncbi.nlm.nih.gov/19699182Test
